Sol-Gel Reports Q4 Loss of $1.07, Files 2025 Form 20-F with Pipeline Update
Sol-Gel posted a Q4 net loss of $1.07 per share versus a $0.39 per-share profit estimate and fell short of revenue targets. The company filed its Form 20-F for fiscal 2025, detailing audited financials and pipeline progress including Phase 3 candidate SGT-610.
1. Q4 Earnings and Performance
Sol-Gel posted a fourth-quarter net loss of $1.07 per share, missing the consensus estimate of a $0.39-per-share profit and falling below revenue forecasts. The shortfall reflects higher R&D spending on its dermatology pipeline and lower product sales compared to expectations.
2. Annual Report Filing
The company filed its Form 20-F for the fiscal year ended December 31, 2025, which includes audited financial statements, management discussion and analysis, and disclosures on corporate governance. Shareholders can request a hard copy of the complete report free of charge for detailed insights into balance sheet and cash flow positions.
3. Pipeline Progress
Sol-Gel’s lead investigational candidate, SGT-610 (patidegib gel, 2%), is in Phase 3 for Gorlin syndrome with orphan and breakthrough designations and may expand to high-frequency basal cell carcinoma upon approval. The company is also advancing SGT-210, an EGFR inhibitor, and markets two FDA-approved products, TWYNEO® and EPSOLAY®, targeting rare skin diseases.